key: cord-0686416-7m1w9ato
authors: Aiello, Alessandra; Fard, Saeid Najafi; Petruccioli, Elisa; Petrone, Linda; Vanini, Valentina; Farroni, Chiara; Cuzzi, Gilda; Navarra, Assunta; Gualano, Gina; Mosti, Silvia; Pierelli, Luca; Nicastri, Emanuele; Goletti, Delia
title: Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
date: 2021-04-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.034
sha: b06a9cdbc6d06e6d2df77e263d701563d07cda1b
doc_id: 686416
cord_uid: 7m1w9ato

OBJECTIVES: To identify the best experimental approach to detect a SARS-CoV-2-specific T cell response using a whole-blood platform. METHODS: Whole-blood from 56 COVID-19 and 23 “NO-COVID-19” individuals were overnight stimulated with different concentrations (0.1 or 1 µg/mL) of SARS-CoV-2 PepTivator® Peptide Pools, including spike (pool S), nucleocapsid (pool N), membrane (pool M), and a MegaPool (MP) of these three peptide pools. ELISA was used to analyse IFN-γ levels. RESULTS: IFN-γ-response to every SARS-CoV-2 peptide pool was significantly increased in COVID-19 patients compared with “NO-COVID-19” individuals. Pool S and MegaPool were the most potent immunogenic stimuli (median: 0.51, IQR: 0.14-2.17; and median: 1.18, IQR: 0.27-4.72, respectively) compared to pools N and M (median: 0.22, IQR: 0.032-1.26; and median: 0.22, IQR: 0.01-0.71, respectively). Whole-blood test based on pool S and MegaPool showed a good sensitivity of 77% and a high specificity of 96%. IFN-γ-response was mediated by both CD4(+) and CD8(+) T cells, and detected independently of clinical parameters in both hospitalized and recovered patients. CONCLUSIONS: This easy-to-use assay for detecting SARS-CoV-2-specific T cell response may be implemented in clinical laboratories as a powerful diagnostic tool.

Alessandra Aiello a* , Saeid Najafi Fard a* , Elisa Petruccioli a , Linda Petrone a , Valentina Vanini a,b , Chiara Farroni a , Gilda Cuzzi a , Assunta Navarra c , Gina Gualano d , Currently, the evaluation of population immunity is based on seroprevalence studies, however, in the context of evidence for cellular responses in seronegative Recently, a whole-blood approach has been scouted by us (Petrone et al., 2021a (Petrone et al., , 2021b (Petrone et al., , 2021c and other groups (Murugesan et al., 2020; Echeverría et al., 2021) to evaluate the specific immune response in COVID-19 patients. So far, different experimental approaches and clinical settings have been adopted leading to different results. In particular, regarding the experimental procedures, peptides corresponding to different viral genome regions (spike, membrane, nuclear proteins or others), concentration of peptides, and read-out have been employed. Moreover, different clinical setting involving acute (Petrone et al., 2021a) or convalescent (Murugesan et al., 2020; Echeverría et al., 2021) COVID-19 subjects have been involved. Here, we used a whole-blood interferon (IFN)-γ release assay (IGRA) to characterize the IFN-γ response to different SARS-CoV-2 peptides in acute hospitalized and post-acute non-hospitalized COVID-19 patients, and to identify the best experimental approach to detect a SARS-CoV-2-specific T cell response.

The prospective study was approved by the Ethical Committee of Lazzaro Spallanzani National Institute of Infectious Diseases (INMI) (approval number 59/2020) and was conducted between December 10 th 2020 and February 5 th 2021. Informed, written consent was required to consecutively enroll patients and controls by physicians. Demographic and clinical information were collected at enrollment. Exclusion criteria were: HIV infection, inability to sign an informed consent and age younger than 18 years.

The hospitalized COVID-19-patients were classified as mild, moderate, severe and critical according to WHO (WHO); we reported the highest severity score of the disease occurring during the hospitalization. Briefly, mild COVID-19 patients had symptoms but did not have viral pneumonia or hypoxia; moderate COVID-19 patients had pneumonia and SpO2 ≥90% on room air; severe COVID-19 patients had pneumonia and a respiratory rate > 30 breaths/min or severe respiratory distress or SpO2< 90% on room air; critical COVID-19 patients had acute respiratory distress syndrome. 

Whole-blood (600 µL) was stimulated or not with two different concentrations (0.1 µg/mL and 1 µg/mL) of different peptide pools. Staphylococcal Enterotoxin B (SEB) (Sigma-Aldrich, Milan, Italy) (200 ng/mL) was used as positive control. Plasma was harvested after overnight (20-24 h) stimulation in a 48-well flat-bottom plate at 37°C (5% CO2) and stored at -80°C. IFN-γ levels were evaluated by enzyme-linked immunosorbent assay (ELISA), according to manufacturer's instructions (www.quantiFERON.com). IFN-γ values were subtracted from the unstimulated-control. The lower and upper detection limits of the test were 0.065 and 10 IU/mL, respectively.

Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll density gradient centrifugation (Pancoll human, PAN Biotech, Germany) and resuspended in complete RPMI-1640 medium, with 10% Fetal Bovine Serum, 1% L-Glutamine, 1% Penicillin/Streptomycin (Euroclone S.p.A, Italy).

To characterize the specific T cell response by flow cytometry, fresh 1x10 6 PBMCs were resuspended in 1 mL of complete medium and stimulated with pools S, N, M at 0.1 µg/mL, and SEB (200 ng/mL) as positive control. Anti-CD28 and anti-CD49d monoclonal antibodies (mAbs) at 2 µg/mL each, were added to co-stimulate cells. After 1 hour, 1 µL/1x10 6 of Golgi plug (BD Biosciences San Jose, USA) was added to each sample to inhibit cytokine secretion, according to manufacturer's instruction. Following an incubation of 16-24h, cells were stained as described below.

J o u r n a l P r e -p r o o f 8 PBMCs were stained with fluorochrome conjugated antibodies according to the standard operating procedure. T cells were stained with the following antibodies:

CD3 phycoerythrin-cyanine 7 (PE-Cy7), CD4 Brilliant Violet (BV)711 and CD8 allophycocyanin-H7 (APC-H7) (all from BD Biosciences). The Cytofix/Cytoperm kit (BD Biosciences) was used for sub sequential intracellular staining of IFN-γ allophycocyanin (APC). Dead cells were excluded from analysis by side/forward scatter gating at first and then by Fixable Viability stain 700 (BD Biosciences). At least 100,000-gated events on living cells were analysed, whenever possible, for each sample. Samples were acquired on a BD Lyric (BD Biosciences) cytometer. Data were analysed with FlowJo software, version 10 (Tree Star).

SARS-CoV-2 specific IgM and IgG levels were measured by ELISA according to manufacturer's instructions (DIESSE Diagnostica Senese S.p.a., Monteriggioni, Italy). The ratio between the optical density (OD) of the sample and that of the cut-off reagent (index) was calculated. The samples were scored positive (index >1.1), doubtful (index between 1.1 and 0.9), and negative (index < 0.9).

Data were analysed using Graph Pad ( STATA for testing the equality of ROC areas; Spearman's Rank Correlation for correlations, and rs>0.7 was considered high correlation, 0.7 <rs>0.5 moderate correlation and rs<0.5 low correlation.

We prospectively enrolled 56 (47 acute hospitalized and 9 recovered non-hospitalized) COVID-19 patients and 23 "NO-COVID-19" subjects. COVID-19 patients were classified based on days from symptoms onset and disease severity, as reported in Table 1 . A higher proportion of acute-hospitalized patients had a severe or critical illness compared with recovered patients (p <0.0001). Demographic and clinical information are detailed in Table 1 .

First, we aimed to evaluate the optimum concentration of viral peptides to use in the whole-blood platform. We performed a dose concentration-response analysis of (Fig. S1 F-I) . The comparison of the ROC curves showed no significant differences in terms of accuracy between the whole-blood test based on peptide pools used at 0.1 µg/mL and at 1 µg/mL (Table 2) . Therefore, the hereafter experiments were performed using the 0.1 µg/mL concentration for pools S, M, and MP. For the pool N, the concentration of 1 µg/mL was chosen due to a higher accuracy found at 1 µg/mL compared to the 0.1 µg/mL concentration.

Once identified the best concentration for each peptide pool, we implemented the initial cohort of subjects reaching the number of 56 COVID-19 and 23 "NO-COVID-19" individuals. As expected, we found that the IFN-γ levels in response to pools N, M, S and MP stimulations were significantly higher in COVID-19 compared to "NO-COVID-19" individuals (p<0.0001, p=0.0005, p<0.0001, and p<0.0001, respectively) ( Fig. 1 A, C The ROC analyses performed on the larger cohort confirmed the accuracy of the test for the diagnosis of COVID-19 showing significant and even high AUC for pools S (AUC=0.90, p<0.0001) and MP (AUC=0.89, p<0.0001), followed by pools N (AUC=0.81, p<0.0001) and M (AUC=0.74, p=0.0008) (Fig. 1 B, D, F, H) . Based on the likelihood ratio, we defined the cut-off for scoring purposes (0.13 IU/mL for the IFN-γ response to pool S and 0.24 IU/mL for MP) identifying a good sensitivity of 77% and a high specificity of 96% for both pools S and MP. For pools N and M, we defined a cut-off of 0.13 IU/mL and 0.19 IU/mL, respectively, which showed a sensitivity of 61% for pool N and 52% for pool M, and a specificity of 96% for pool N and 91% for pool M, respectively. 

To define the T cell subsets responsible for the SARS-CoV-2 immune response, we evaluated the ability of T cells to produce IFN-γ in response to stimulation with pools S, N, and M by flow cytometry. The analysis was performed on fresh PBMCs isolated from a cohort of 3 hospitalized COVID-19 patients. We demonstrated that all COVID-19 patients responded to SEB stimulation (Fig. 2 A) and that SARS-CoV-2 response was mediated by both CD4 + and CD8 + T cells (Fig. 2 B, C) .

To evaluate whether the IFN-γ response was associated with the acute phase of the disease, we stratified the COVID-19 patients according to the hospitalization status. No significant differences were observed in the IFN-γ levels in response to all stimuli between acute hospitalized and post-acute non-hospitalized (recovered) COVID-19 patients (Fig. 3) .

Within acute hospitalized COVID-19 patients, we evaluated the characteristics of patients as potential factors impacting the IFN-γ response to SARS-CoV-2 peptides (Table 3) 

Acute hospitalized COVID-19 patients were stratified based on the serology results. We included patients who had doubtful serology only for IgG (n = 1) or IgM (n = 3) in the IgG + /IgM + group. No significant differences in the IFN-γ levels were found in response to pools N (p = 0.43), M (p = 0.39), S (p = 0.63) or MP (p = 0.34) (Fig. 4) . Interestingly, the IFN-γ response was detected even in 7 patients scored IgG-and IgM-negative, that showed a higher IFN-γ response to the pools S and MP (median: 1.22, IQR 0.20-5.41; median: 1.54, IQR 0.57-9.65, respectively) compared to pools N and M (median: 0.17, IQR 0.03-1.60; median: 0.26, IQR 0-0.51, respectively). Surprisingly, among the patients scored negative to IgG/IgM, there was one patient whose symptoms onset dated back to 6 days before the time of blood stimulation and became IgG-positive after 5 days from the IFN-γ blood test.

In this study we demonstrated in a cohort of hospitalized COVID-19 patients, COVID-19-recovered individuals and COVID-19-unexposed subjects that an IFN-γ test based on whole blood stimulated with SARS-CoV-2 specific peptide pools corresponding to spike, nucleoprotein, membrane or a mix of them, has a good accuracy to discriminate COVID-19-hospitalized or -recovered patients from healthy unexposed individuals. Among the stimuli used, the best was the pool S, followed by MP, pool N, and pool M. Interestingly, the T cell response was found also in individuals scored negative to SARS-CoV-2 serology. Moreover, by flow cytometry, we showed that the specific response to pool S, N and M was mediated by both CD4 + and CD8 + T cells. This T cell-based test may be a good approach to study the specific response in COVID-19 patients during the acute phase, at recovery and likely in SARS-CoV-2-vaccinated individuals (Manisty et al., 2021) .

The assay described in the present study has a higher accuracy compared to whole-blood tests described so far by us (Petrone et al., 2021a (Petrone et al., , 2021b (Petrone et al., , 2021c Mizukoshi et al., 2008) . Interestingly, in the present study we found T cell response in 7 hospitalized COVID-19 patients who scored negative to both IgM and IgG SARS-CoV-2 serology. Within this group there were 5 patients whose symptoms onset dated back to 1-8 days before blood stimulation. Particularly, one patient had IgG seroconversion after five days from the test. These data suggest that the IFN-γ T cell response might anticipate in some cases the B cell response as detected J o u r n a l P r e -p r o o f 14 by antibody. This result is interesting and may offer clinical diagnostic applications. Considering that SARS-CoV-2-IgG or IgM levels are not constant over time (Sethuraman et al., 2020; Xiao et al., 2020) , beside serology, IFN-γ release assay (IGRA) may be a potential additional immune tool for further diagnostic and clinical deeper evaluations. The test may be used, as an easy-to-use assay to better understand the prevalence of T cell specific immunity in the population, access of the pre-existing T cell immunity in seronegative individuals, vaccine-induced immunity, and also to pre-evaluate the SARS-CoV-2 vaccine candidates in clinical trials.

The present study has some limitations. The sample size is relatively small (79 subjects) and not representative of the whole COVID-19 or "NO-COVID-19" population. Moreover, we did not perform any longitudinal analyses of specific T-cell response and antibodies to evaluate the levels of specific immunity over time.

These issues may be assessed in future studies.

In conclusion, we provided a simple IGRA platform for SARS-CoV-2-specific immune response detection which can be easily scaled up for population-based studies. This test can be implemented in clinical laboratories as a powerful diagnostic tool and for understanding vaccine efficacy and potentially for surveillance strategies. 

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in

as detected with a COVID-19 Interferon-Gamma Release Assay

Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use

The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease

Can we predict tuberculosis cure? What tools are available?

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study

Interferon-γ Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice?

Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

Antibody responses to SARS-CoV-2 in patients with COVID-19

Early detection of Toxoplasma gondii infection by using a interferon gamma release assay: A review

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina

A whole blood test to measure SARS-CoV-2-specific response

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

Interpreting Diagnostic Tests for SARS-CoV-2

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

T cell response to SARS-CoV-2 infection in humans: A systematic review

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Immunology of COVID-19: Current State of the Science

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins

The authors are grateful to all the patients and nurses who helped to conduct this study. The authors gratefully